Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain

[1] Villemagne VL(2015)Tau imaging: early progress and future directions Lancet Neurol 14 114-24

[2] Fodero-Tavoletti MT(2016)Tau positron emission tomographic imaging in aging and early Alzheimer disease Ann Neurol 79 110-9

[3] Masters CL(2015)18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer’s disease J Nucl Med 57 1-43

[4] Rowe CC(1987)Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET Science 235 481-5

[5] Johnson KA(2013)Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies J Cereb Blood Flow Metab 33 863-71

[6] Schultz A(2003)1-methyl-2-undecyl-4(1H)-quinolone as an irreversible and selective inhibitor of type B monoamine oxidase Chem Pharm Bull (Tokyo) 51 409-11

[7] Betensky RA(1997)Clinical pharmacokinetics and pharmacodynamics of selegiline. An update Clin Pharmacokinet 33 91-102

[8] Becker JA(1975)“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 189-98

[9] Sepulcre J(2004)Mild cognitive impairment as a diagnostic entity J Intern Med 256 183-94

[10] Rentz D(2011)Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease Neurology 77 333-9

[1] Villemagne VL(2015)Tau imaging: early progress and future directions Lancet Neurol 14 114-24

[2] Fodero-Tavoletti MT(2016)Tau positron emission tomographic imaging in aging and early Alzheimer disease Ann Neurol 79 110-9

[3] Masters CL(2015)18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer’s disease J Nucl Med 57 1-43

[4] Rowe CC(1987)Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET Science 235 481-5

[5] Johnson KA(2013)Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies J Cereb Blood Flow Metab 33 863-71

[6] Schultz A(2003)1-methyl-2-undecyl-4(1H)-quinolone as an irreversible and selective inhibitor of type B monoamine oxidase Chem Pharm Bull (Tokyo) 51 409-11

[7] Betensky RA(1997)Clinical pharmacokinetics and pharmacodynamics of selegiline. An update Clin Pharmacokinet 33 91-102

[8] Becker JA(1975)“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 189-98

[9] Sepulcre J(2004)Mild cognitive impairment as a diagnostic entity J Intern Med 256 183-94

[10] Rentz D(2011)Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease Neurology 77 333-9